EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

CD24 is a promising immunotherapeutic target for enhancing efficacy of third‐generation EGFR‐TKIs on EGFR‐mutated lung cancer

Jiaqi Liang, Guoshu Bi, Xiaolong Huang, Zhijie Xu, Yiwei Huang, Yunyi Bian, Guangyao Shan, Wei Guo, Yuanliang Yan, Qihai Sui, Xiaodong Yang, Zhencong Chen und 5 weitere

Cancer Communications · 2025-11 · 45 (11) · 1547-1578

DOI: 10.1002/cac2.70068 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Communications, online erschienen am 13.10.2025. Verfasst von Jiaqi Liang und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, P. R. China. Hauptthemen laut MEDLINE: Lung Neoplasms, Protein Kinase Inhibitors, CD24 Antigen. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 97 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Shanghai Sailing Program, Natural Science Foundation of Shanghai Municipality.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Third‐generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) show initial efficacy in EGFR‐mutated lung cancer, but residual disease persists. This study aimed to investigate cluster of differentiation 24 (CD24) as a translational immunotherapeutic target for enhancing third‐generation EGFR‐TKI efficacy.

Methods

We conducted RNA‐sequencing (RNA‐seq) on drug‐responsive, drug‐tolerant persister, and drug‐resistant cells to identify therapeutic targets to pair with EGFR‐TKIs. For validation, we integrated single‐cell RNA‐seq data from 29 lung cancer specimens and used single‐nucleus RNA‐seq and immunohistochemistry on clinical residual tumor samples following TKI therapy (TKI‐residual). With CRISPR/Cas9, we studied the effect of CD24 on proliferation and phagocytic clearance during EGFR‐TKI treatment. We tested CD24 knockout or ATG‐031 (a first‐in‐class CD24 antibody) with EGFR‐TKIs in vitro, xenografts, and spontaneous lung cancer models. To explore mechanisms, we used DNA affinity precipitation, chromatin immunoprecipitation sequencing, and luciferase assays to identify transcription factors regulating CD24. Co‐immunoprecipitation combined with mass spectrometry and phosphoproteomics were used to study YIN‐YANG‐1 (YY1) S247 phosphorylation's expression and function, while kinase inhibitors assessed upstream phosphorylation of YY1 S247 and its regulation of CD24.

Results

CD24 expression rose in drug‐responsive, ‐resistant, and ‐tolerant lung cancer cells and post‐EGFR‐TKI treatment clinical specimens. This elevation promoted cell proliferation and shielded tumor cells from macrophage‐mediated phagocytosis. Genetic depletion of CD24 or treatment with ATG‐031 significantly enhanced phagocytosis and tumor eradication in vitro, in xenografts, and in mice harboring EGFRL858R·T790M‐driven spontaneous lung tumors. Furthermore, we revealed that YY1 S247 phosphorylation was responsible for the upregulation of CD24 upon EGFR‐TKI treatment, facilitating YY1 dimerization and the formation of promoter‐enhancer loops that regulate CD24 expression.

Conclusions

CD24 is a promising target in EGFR‐mutated lung cancers, potentially enhancing efficacy of third‐generation EGFR‐TKIs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsProtein Kinase InhibitorsCD24 AntigenHumansAnimalsErbB ReceptorsMiceMutationCell Line, TumorDrug Resistance, NeoplasmXenograft Model Antitumor AssaysYY1 Transcription FactorFemaleCell ProliferationImmunotherapy

Stichwörter der Autor:innen

ATG‐031CD24EGFR‐TKIJNKYY1drug‐tolerant persister celllung cancerosimertinibphagocytosis

Substanzen

Protein Kinase InhibitorsErbB ReceptorsCD24 AntigenEGFR protein, humanCD24 protein, humanYY1 Transcription FactorYY1 protein, human

Autor:innen und Institutionen

  • Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, P. R. China.
  • Cancer Center, Zhongshan Hospital, Fudan University, Shanghai, P. R. China.
  • Department of Pathology, Xiangya Hospital, Central South University, Changsha, Hunan, P. R. China.
  • Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, P. R. China.
  • Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, Hunan, P. R. China.
  • Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University, Shanghai, P. R. China.

ORCID-Profile: Cheng Zhan

Förderung

  • National Natural Science Foundation of China
  • Shanghai Sailing Program
  • Natural Science Foundation of Shanghai Municipality
  • Beijing Xisike Clinical Oncology Research Foundation

Zitieren

APA

Liang, J., Bi, G., Huang, X., Xu, Z., Huang, Y., Bian, Y., Shan, G., Guo, W., Yan, Y., Sui, Q., Yang, X., Chen, Z., Lu, T., Zhang, H., Wang, Q., Jiang, W., & Zhan, C. (2025). CD24 is a promising immunotherapeutic target for enhancing efficacy of third‐generation EGFR‐TKIs on EGFR‐mutated lung cancer. Cancer Communications, 45(11), 1547-1578. https://doi.org/10.1002/cac2.70068

Vancouver

Liang J, Bi G, Huang X, Xu Z, Huang Y, Bian Y, et al. CD24 is a promising immunotherapeutic target for enhancing efficacy of third‐generation EGFR‐TKIs on EGFR‐mutated lung cancer. Cancer Communications. 2025;45(11):1547-1578. doi:10.1002/cac2.70068

BibTeX
@article{Liang2025,
  author = {Liang, Jiaqi and Bi, Guoshu and Huang, Xiaolong and Xu, Zhijie and Huang, Yiwei and Bian, Yunyi and Shan, Guangyao and Guo, Wei and Yan, Yuanliang and Sui, Qihai and Yang, Xiaodong and Chen, Zhencong and Lu, Tao and Zhang, Huan and Wang, Qun and Jiang, Wei and Zhan, Cheng},
  title = {CD24 is a promising immunotherapeutic target for enhancing efficacy of third‐generation EGFR‐TKIs on EGFR‐mutated lung cancer},
  journal = {Cancer Communications},
  year = {2025},
  volume = {45},
  number = {11},
  pages = {1547--1578},
  doi = {10.1002/cac2.70068}
}
Kostenlos starten →